Disease · MONDO_0005132
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Valganciclovir 900 mg BID vs Maribavir 400 mg BID: deaths from any cause | 29 of 277 | 37 of 276 | 553 | NCT02927067 | Trial comparisons |
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants Who Achieved Confirmed CMV Viremia Clearance and CMV Infection Symptom Control at the End of Week 8, Followed by Maintenance of Treatment Effect at Week 16 | 133 of 274 | 144 of 273 | 547 | NCT02927067 | Trial comparisons |
| Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribose Nucleic Acid (DNA) at the End of Study Week 8 | 212 of 274 | 190 of 273 | 547 | NCT02927067 | Trial comparisons |
| Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants Developing Resistance | 8 of 274 | 24 of 273 | 547 | NCT02927067 | Trial comparisons |
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants Who Achieved Confirmed Clearance of Plasma CMV DNA (CMV Viremia Clearance) at Week 8 After Receiving 8 Weeks of Study Assigned Treatment | 137 of 274 | 158 of 273 | 547 | NCT02927067 | Trial comparisons |
| Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants With Treatment-Emergent Adverse Events During the On-Treatment Period | 269 of 274 | 268 of 273 | 547 | NCT02927067 | Trial comparisons |
| Valganciclovir 900 mg BID vs Maribavir 400 mg BID: serious adverse events | 95 of 274 | 88 of 273 | 547 | NCT02927067 | Trial comparisons |
| Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants With Confirmed Recurrence of Viremia During the Follow-up Period | 47 of 236 | 27 of 226 | 462 | NCT02927067 | Trial comparisons |
| Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants With Confirmed Recurrence of Viremia at Any Time During the Study | 53 of 236 | 43 of 226 | 462 | NCT02927067 | Trial comparisons |
| Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants With Confirmed Recurrence of Viremia During First 8 Weeks of the Study | 6 of 236 | 16 of 226 | 462 | NCT02927067 | Trial comparisons |
| Investigator-assigned Anti-CMV Treatment (IAT) vs Maribavir 400 mg: Number of Participants With All-cause Mortality by the End of the Study | 13 of 117 | 27 of 235 | 352 | NCT02931539 | Trial comparisons |
| Letermovir vs No Anti-CMV Treatment: Occurrence of Grade ≥3 AEs or Confirmed HIV-1 Virologic Failure | 5 of 19 | 2 of 22 | 41 | NCT04840199 | Trial comparisons |
| Letermovir vs No Anti-CMV Treatment: deaths from any cause | 0 of 19 | 0 of 22 | 41 | NCT04840199 | Trial comparisons |
| Letermovir vs No Anti-CMV Treatment: serious adverse events | 1 of 19 | 1 of 22 | 41 | NCT04840199 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005132/comparisons